Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This specific oral combined hormonal contraceptive (OC) formulation consists of 20 mcg of ethinyl estradiol (a synthetic estrogen) and 1 mg of norethindrone acetate (a progestin). In the context of polycystic ovary syndrome (PCOS), particularly in women of later reproductive age (40-49 years), it is used as a first-line medical therapy to manage clinical and biochemical hyperandrogenism, regulate menstrual cycles, and prevent endometrial hyperplasia by inducing regular withdrawal bleeding. The University of Virginia studied this formulation in a randomized, double-blind, crossover trial (NCT03905941) to determine its relative desirability and efficacy compared to metformin, using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) score as a proxy for patient satisfaction. The mechanism involves the suppression of pituitary gonadotropin secretion, which inhibits ovulation and reduces ovarian androgen production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinyl estradiol + norethindrone acetate.